

**In the Claims:**

The following listing reflects amendments to the claims and replaces all prior versions and listings of claims in this application.

1-16 (canceled)

17. (Currently amended) An immunogenic composition comprising a first antigen and a second antigen, wherein: (a) the first antigen is an oligosaccharide from serogroup C of *N. meningitidis* (NmC) conjugated to a carrier; and (b) the second antigen is proteoliposomic vesicles from serogroup B of *N. meningitidis* (NmB).

18. (Previously presented) The composition of claim 17, wherein said first antigen is conjugated to a protein carrier.

19. (Currently amended) The composition of claim 18, wherein said protein carrier is CRM<sub>197</sub>.

20. (Currently amended) The composition of claim 17, wherein said NmC oligosaccharide contains about 12 to about 22 repeating units from *N. meningitidis* serogroup C capsular polysaccharide.

21. (Previously presented) The composition of claim 17, wherein said NmB is strain 44/76 (B15:P1.7, 16:L3,7,9).

22. (Currently amended) The composition of claim 17, wherein said proteoliposomic vesicles are produced by a deoxycholate extraction process.

23. (Previously presented) The composition of claim 17, wherein said composition further comprises aluminum hydroxide or MF59.

24. (Currently amended) The composition of claim 17, wherein said composition comprises a carrier comprising polylactic acids ~~and/or~~ or polyglycolic acids.

25. (Previously presented) The composition of claim 17, wherein said composition comprises immunologically effective amounts of the first and the second antigen.

26. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a first antigen and an immunologically effective amount of a second antigen, wherein: (a) the first antigen is an oligosaccharide from serogroup C of *N. meningitidis* (NmC), conjugated to CRM<sub>197</sub>, and contains from 12 to 22 repeating units from the NmC capsular polysaccharide and (b) the second antigen is proteoliposomic vesicles from strain 44/76 (B15:P1.7, 16:L3,7,9) of serogroup B of *N. meningitidis* (NmB), wherein said proteoliposomic vesicles are produced by a deoxycholate extraction process.

27. (Previously presented) The composition of claim 26, wherein said composition further comprises aluminum hydroxide or MF59.

28. (Currently amended) The composition of claim 26, wherein said composition comprises a carrier comprising polylactic acids ~~and/or~~ or polyglycolic acids.

29. (Withdrawn) A method of inducing an immunologic

response to NmB and NmC in a mammalian subject, comprising administering an immuologically effective amount of an immunogenic composition of any of claims 17-28 to said mammalian subject.